[Treatment with cyclosporine of severe colitis in hemorrhagic rectocolitis. Apropos of 7 cases].
Cyclosporin has been suggested as an alternative treatment in severe acute ulcerative colitis. In a retrospective study, the outcome of seven ulcerative colitis patients treated by intravenous cyclosporin (mean dose 3.6 mg/kg/day) has been evaluated. Short-term results indicated full remission in 3/7 (43%) patients. At long term follow-up (one year), only 2/7 patients could avoid ileal pouch-anal anastomosis. Two complications (one colonic perforation and one septicemia) were observed. Our results suggest that intravenous cyclosporin should not be recommended as a standard therapy in severe acute ulcerative colitis. Its use has to be limited in patients presenting a major contraindication for surgery and has to be performed by those experienced in both immunosuppressive treatment and inflammatory bowel disease.
Reimund
J M
JM
Service d'Hépato-Gastroentérologie et d'Assistance Nutritive, Hôpitaux Universitaires de Strasbourg, Hôpital de Haute-pierre.
Duclos
B
B
Baumann
R
R
D000208:Acute Disease; D000328:Adult; D003092:Colitis / Q000188:drug therapy; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000503:physiopathology; D016572:Cyclosporine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D013997:Time Factors
D007166:Immunosuppressive Agents; D016572:Cyclosporine
Traitement par la ciclosporine des colites graves au cours de la rectocolite hémorragique. A propos de 7 observations.